FDA accepts the Pharmacosmos facility

February 12, 2005

Pharmacosmos has received the official accept from the US Food & Drug Administration (FDA) for the manufacturing of dextran and iron dextran compounds.

About Pharmacosmos A/S

Pharmacosmos develops and markets medicines for the treatment of iron deficiency. A research-based company, its ongoing R&D programme focuses on improving the treatment options for healthcare professionals, patients suffering from iron deficiency and veterinary treatments. .

Pharmacosmos is a family-owned Danish company and operates in more than 50 countries across Europe, the Americas and Asia. Its facilities are approved by both the Danish Medicines Agency and the US Food & Drug Administration.